MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202617077809 A) filed by Kissei Pharmaceutical Co. , Ltd. on June 24, 2026, for Therapeutic Agent For Neurodegenerative Disorder.
Inventors include Furihata, Takao; Sakuwa, Yoshihiro; Oikawa, Junichi; and Umezawa, Yuko.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson’s disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8- methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.
Disclaimer: Curated by HT Syndication.
